Effects of diverse psychopharmacological substances on the activity of brain prolyl oligopeptidase

Basic and Clinical Pharmacology and Toxicology

Volumn 108, Issue 1, 2011, Pages 46-54

  Peltonen, Iida ^a   Männistö, Pekka T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BUSPIRONE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUPENTIXOL; IMIPRAMINE; KETANSERIN; LAMOTRIGINE; LEVOMEPROMAZINE; MOOD STABILIZER; NEUROLEPTIC AGENT; NEUROPEPTIDE; PHOSPHATIDYLINOSITOL; PRAZOSIN; PROCHLORPERAZINE; PROLYL ENDOPEPTIDASE; PROMAZINE; PSYCHOTROPIC AGENT; RISPERIDONE; RITANSERIN; THIORIDAZINE; UNINDEXED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; DEEP SEDATION; DRUG BRAIN LEVEL; DRUG EFFECT; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; EX VIVO STUDY; IN VIVO STUDY; LEARNING; LIPOPHILICITY; MALE; MEMORY; MOOD; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SECOND MESSENGER; SINGLE DRUG DOSE;

ANIMALS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; PSYCHOTROPIC DRUGS; RATS; RATS, WISTAR; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; THIORIDAZINE;

MUS; RATTUS;

EID: 78650213420     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2010.00626.x     Document Type: Article

References (48)

1. Männistö PT, Venäläinen J, Jalkanen A, García-Horsman JA. Prolyl oligopeptidase: A potential target for the treatment of cognitive disorders. Drug News Perspect 2007;20:293-305.
2. Maes M, Goossens F, Scharpe S, Meltzer HY, D'Hondt P, Cosyns P. Lower serum prolyl endopeptidase enzyme activity in major depression: Further evidence that peptidases play a role in the pathophysiology of depression. Biol Psychiatry 1994;35:545-52.
3. Maes M, Goossens F, Scharpe S, Calabrese J, Desnyder R, Meltzer HY. Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: Effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiatry Res 1995;58:217-25.
4. Koida M, Walter R. Post-proline cleaving enzyme. Purification of this endopeptidase by affinity chromatography. J Biol Chem 1976;251:7593-9.
5. Williams RS, Eames M, Ryves WJ, Viggars J, Harwood AJ. Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1, 4, 5) trisphosphate. EMBO J 1999;18:2734-45.
6. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: A unifying hypothesis. Cell 1989;59:411-9.
7. Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature 2002;417:292-5.
8. Harwood AJ. Neurodevelopment and mood stabilizers. Curr Mol Med 2003;3:472-82.
9. Harwood AJ, Agam G. Search for a common mechanism of mood stabilizers. Biochem Pharmacol 2003;66:179-89.
10. Arif M, Chikuma T, Ahmed MM, Yoshida S, Kato T. Suppressive effect of clozapine but not haloperidol on the increases of neuropeptide-degrading enzymes and glial cells in MK-801-treated rat brain regions. Neurosci Res 2007;57:248-58.
11. Cheng L, Lumb M, Polgar L, Mudge AW. How can the mood stabilizer VPA limit both mania and depression? Mol Cell Neurosci 2005;29:155-61.
12. Venäläinen JI, Juvonen RO, Forsberg MM, García-Horsman A, Poso A, Wallén EA et al. Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819. Biochem Pharmacol 2002;64:463-71.
13. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
14. Copeland RA. Lead optimization and structure-activity relationships for reversible inhibitors. In: Copeland RA (ed.). Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists. John Wiley & Sons, Inc., Hoboken, 2005;111-40.
15. Cha S. Tight-binding inhibitors-I. Kinetic behavior. Biochem Pharmacol 1975;24:2177-85.
16. Di Daniel E, Glover CP, Grot E, Chan MK, Sanderson TH, White JH et al. Prolyl oligopeptidase binds to GAP-43 and functions without its peptidase activity. Mol Cell Neurosci 2009;41:373-82.
17. Regenthal R, Krueger M, Koeppel C, Preiss R. Drug levels: Therapeutic and toxic serum/plasma concentrations of common drugs. J Clin Monit Comput 1999;15:529-44.
18. Schroeder DH. Metabolism and kinetics of bupropion. J Clin Psychiatry 1983;44:79-81.
19. Rambeck B, Schnabel R, May T, Jurgens U, Villagran R. Postmortem concentrations of phenobarbital, carbamazepine, and its metabolite carbamazepine-10, 11-epoxide in different regions of the brain and in the serum: Analysis of autoptic specimens from 51 epileptic patients. Ther Drug Monit 1993;15:91-8.
20. Van Belle K, Sarre S, Ebinger G, Michotte Y. Brain, liver and blood distribution kinetics of carbamazepine and its metabolic interaction with clomipramine in rats: A quantitative microdialysis study. J Pharmacol Exp Ther 1995;272:1217-22.
21. Tsuneizumi T, Babb SM, Cohen BM. Drug distribution between blood and brain as a determinant of antipsychotic drug effects. Biol Psychiatry 1992;32:817-24.
22. Hyttel J, Overo KF, Arnt J. Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram. Psychopharmacology (Berl) 1984;83:20-7.
23. Wikell C, Apelqvist G, Carlsson B, Hjorth S, Bergqvist PB, Kugelberg FC et al. Pharmacokinetic and pharmacodynamic responses to chronic administration of the selective serotonin reuptake inhibitor citalopram in rats. Clin Neuropharmacol 1999;22:327-36.
24. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 1993;9:117-24.
25. Hrdina PD, Dubas TC. Brain distribution and kinetics of desipramine in the rat. Can J Physiol Pharmacol 1981;59:163-7.
26. Wala EP, Martin WR, Sloan JW. Brain-plasma distribution of free and total benzodiazepines in dogs physically dependent on different doses of diazepam. Pharmacol Biochem Behav 1995;52:707-13.
27. Turcotte JE, Debonnel G, de Montigny C, Hebert C, Blier P. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology 2001;24:511-21.
28. Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007;46:281-90.
29. Henry ME, Schmidt ME, Hennen J, Villafuerte RA, Butman ML, Tran P et al. A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: A 19-F MRS study. Neuropsychopharmacology 2005;30:1576-83.
30. Renshaw PF, Guimaraes AR, Fava M, Rosenbaum JF, Pearlman JD, Flood JG et al. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Am J Psychiatry 1992;149:1592-4.
31. Wille SM, De Letter EA, Piette MH, Van Overschelde LK, Van Peteghem CH, Lambert WE. Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography-mass spectrometry. Int J Legal Med 2009;123:451-8.
32. Bolo NR, Hode Y, Nedelec JF, Laine E, Wagner G, Macher JP. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 2000;23:428-38.
33. Karson CN, Newton JE, Livingston R, Jolly JB, Cooper TB, Sprigg J et al. Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci 1993;5:322-9.
34. Sunderland T, Cohen BM. Blood to brain distribution of neuroleptics. Psychiatry Res 1987;20:299-305.
35. Korzeniewska-Rybicka I, Plaznik A. Analgesic effect of antidepressant drugs. Pharmacol Biochem Behav 1998;59:331-8.
36. van Wijk M, Korf J. A quantitative study in the rat on the relationship between imipramine levels in brain and serum. Psychopharmacology (Berl) 1982;76:48-51.
37. Michiels M, Monbaliu J, Meuldermans W, Hendriks R, Geerts R, Woestenborghs R et al. Pharmacokinetics and tissue distribution of ketanserin in rat, rabbit and dog. Arzneimittelforschung 1988;38:775-84.
38. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993;25:433-43.
39. Kornhuber J, Weigmann H, Rohrich J, Wiltfang J, Bleich S, Meineke I et al. Region specific distribution of levomepromazine in the human brain. J Neural Transm 2006;113:387-97.
40. Soares JC, Boada F, Spencer S, Mallinger AG, Dippold CS, Wells KF et al. Brain lithium concentrations in bipolar disorder patients: Preliminary (7)Li magnetic resonance studies at 3 T. Biol Psychiatry 2001;49:437-43.
41. Altamura AC, De Novellis F, Mauri MC, Gomeni R. Plasma and brain pharmacokinetics of mianserin after single and multiple dosing in mice. Prog Neuropsychopharmacol Biol Psychiatry 1987;11:23-33.
42. Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 2003;54:840-6.
43. Dynon MK, Jarrott B, Louis WJ. Tissue distribution and hypotensive effect of prazosin in the conscious rat. J Cardiovasc Pharmacol 1983;5:235-9.
44. Jahns I, Breyer U. The rat brain as a "deep compartment" in the kinetics of a common metabolite of prochlorperazine and perphenazine. Drug Metab Dispos 1976;4:522-9.
45. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmcol 2004;7:415-9.
46. Hirose H, Aoki I, Kimura T, Fujikawa T, Numazawa T, Sasaki K et al. Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3, 3-difluoroc yclopentyl]-2-hydro-xy-2-phenylacetamide: A novel mucarinic antagonist with M(2)-sparing antagonistic activity. J Pharmacol Exp Ther 2001;297:790-7.
47. Clarke A, Brewer F, Johnson ES, Mallard N, Hartig F, Taylor S et al. A new formulation of selegiline: Improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 2003;110:1241-55.
48. Wieser HG. Comparison of valproate concentrations in human plasma, CSF and brain tissue after administration of different formulations of valproate or valpromide. Epilepsy Res 1991;9:154-9.